Cargando…
Carfilzomib-induced pulmonary hypertension with associated right ventricular dysfunction: A case report
Carfilzomib, a selective proteasome inhibitor, is approved for use in relapsed and refractory multiple myeloma. Its link to left ventricular dysfunction is well established but little is known about its effects on the right ventricle. One of its rare complications is pulmonary hypertension, which at...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7890743/ https://www.ncbi.nlm.nih.gov/pubmed/33643656 http://dx.doi.org/10.1177/2050313X21994031 |